<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JRA</journal-id>
<journal-id journal-id-type="hwp">spjra</journal-id>
<journal-id journal-id-type="nlm-ta">J Renin Angiotensin Aldosterone Syst</journal-id>
<journal-title>Journal of the Renin-Angiotensin-Aldosterone System</journal-title>
<issn pub-type="ppub">1470-3203</issn>
<issn pub-type="epub">1752-8976</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1470320312453243</article-id>
<article-id pub-id-type="publisher-id">10.1177_1470320312453243</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>RAAS Working Group Update</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Ruilope</surname><given-names>Luis M</given-names></name>
</contrib>
<aff id="aff1-1470320312453243">Hospital 12 de Octubre and Department of Public Health and Preventive Medicine, Universidad Autonoma, Madrid Email: <email>ruilope@ad-hocbox.com</email></aff>
</contrib-group>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2012</year>
</pub-date>
<volume>13</volume>
<issue>3</issue>
<fpage>408</fpage>
<lpage>408</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>In recent times, a debate has been established about the convenience or inconvenience of dual blockade of the renin-angiotensin-aldosterone system (RAAS) in clinical situations of high cardiovascular (CV) and/or renal risk. We recently reviewed the topic<sup><xref ref-type="bibr" rid="bibr1-1470320312453243">1</xref></sup> and concluded that the answer to the question is negative in patients with an elevated CV risk as a consequence of the absence of positive results with the combination of telmisartan and ramipril, i.e. the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) study. However, the issue of dual blockade in the presence of an increased renal risk fundamentally attributed to the presence of proteinuria was not so clear. In fact, most nephrologists consistently use the combination of an angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor blockers (ARB) in patients in whom single blockade does not diminish proteinuria sufficiently. In these patients the consideration has been and probably continues to be that the primary aim is the protection of the kidney, and no consideration is usually made about the need for simultaneous CV protection.</p>
<p>Recently, three big trials have shown that what turned out to be good for the CV outcome was equally good for the renal outcome. These trials are the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT),<sup><xref ref-type="bibr" rid="bibr2-1470320312453243">2</xref></sup> the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE)<sup><xref ref-type="bibr" rid="bibr3-1470320312453243">3</xref></sup> and Actively Creating COMPLIance Saving Health (ACCOMPLISH).<sup><xref ref-type="bibr" rid="bibr4-1470320312453243">4</xref></sup> This finding is important because it indicates that CV and renal systems must be considered as partners in what we know as cardiorenal disease.</p>
<p>This issue of JRAAS contains the summary of a meeting recently organised to debate the failure of the ALiskiren Trial In Type 2 diabetes Using cardiovascular and renal Disease Endpoints (ALTITUDE) study,<sup><xref ref-type="bibr" rid="bibr5-1470320312453243">5</xref></sup> where the concept of cardiorenal was used in the design of the study that in the composite primary endpoint included the usual CV and renal endpoints. The study was closed because of the futility of the combination of aliskiren and either an ACEi or ARB compared to placebo. In addition, some potential unwanted adverse events, probably mostly related to changes in blood pressure (fundamentally hypotension), were also observed. The article contained in this issue reviews mechanisms explaining these findings, and is really interesting. I will simply add here that in agreement with the three previously mentioned trials, ALTITUDE also proves the need for a cardiorenal concept because what was not good for the CV system was neither good for the kidney, nor vice versa.</p>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-1470320312453243">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Volpe</surname><given-names>M</given-names></name>
<name><surname>Danser</surname><given-names>AH</given-names></name>
<name><surname>Ménard</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?</article-title> <source>J Hypertens</source> <year>2012</year>; <volume>30</volume>: <fpage>647</fpage>–<lpage>654</lpage>.</citation>
</ref>
<ref id="bibr2-1470320312453243">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dahlöf</surname><given-names>B</given-names></name>
<name><surname>Sever</surname><given-names>PS</given-names></name>
<name><surname>Poulter</surname><given-names>NR</given-names></name>
<etal/>
</person-group>. <article-title>Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial</article-title>. <source>Lancet</source> <year>2005</year>; <volume>366</volume>: <fpage>895</fpage>–<lpage>906</lpage>.</citation>
</ref>
<ref id="bibr3-1470320312453243">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ninomiya</surname><given-names>T</given-names></name>
<name><surname>Perkovic</surname><given-names>V</given-names></name>
<name><surname>de Galan</surname><given-names>BE</given-names></name>
<etal/>
</person-group>. <article-title>Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes</article-title>. <source>J Am Soc Nephrol</source> <year>2009</year>; <volume>20</volume>: <fpage>1813</fpage>–<lpage>1821</lpage>.</citation>
</ref>
<ref id="bibr4-1470320312453243">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bakris</surname><given-names>GL</given-names></name>
<name><surname>Sarafidis</surname><given-names>P</given-names></name>
<name><surname>Weir</surname><given-names>MR</given-names></name>
<etal/>
</person-group>. <article-title>Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified analysis of a randomised controlled trial</article-title>. <source>Lancet</source> <year>2010</year>; <volume>375</volume>: <fpage>1173</fpage>–<lpage>1181</lpage>.</citation>
</ref>
<ref id="bibr5-1470320312453243">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parving</surname><given-names>HH</given-names></name>
<name><surname>Brenner</surname><given-names>BM</given-names></name>
<name><surname>McMurray</surname><given-names>JJ</given-names></name><etal/>
</person-group>. <article-title>Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design</article-title>. <source>Nephrol Dial Transplant</source> <year>2009</year>; <volume>24</volume>: <fpage>1663</fpage>–<lpage>1671</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>